SCP
HBIO icon

Seizert Capital Partners’s Harvard Bioscience HBIO Stock Holding History

Seizert Capital Partners’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,402
Closed -$102K – 196
2020
Q3 		$102K Sell
3,402
-1,722
-34% -$57.9K 0.01% 189
2020
Q2 		$159K Sell
5,124
-745
-13% -$20.1K 0.01% 193
2020
Q1 		$130K Buy
+5,869
New +$159K 0.01% 185

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Seizert Capital Partners's HBIO Position: Q4 2020 in Review

Seizert Capital Partners sold out of Harvard Bioscience (HBIO) in Q4 2020, closing a stake of 3,402 shares — an estimated $102K sold.

Seizert Capital Partners first reported a position in HBIO in Q1 2020 and held it in 3 quarters. The position peaked at $159K in Q2 2020. 81 funds tracked by Wall St. Rank hold HBIO as of Q4 2020.

  • Seizert Capital Partners reported no remaining Harvard Bioscience position as of Q4 2020 after selling out during the quarter.
  • Seizert Capital Partners sold 3,402 Harvard Bioscience shares in Q4 2020, an estimated $102K.
  • Seizert Capital Partners first reported a position in Harvard Bioscience in Q1 2020 and held it in 3 quarters.
  • Seizert Capital Partners's Harvard Bioscience position peaked at $159K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2020.

Based on Seizert Capital Partners's 13F filing for Q4 2020, filed 8 Feb 2021.